NCT04931017View on ClinicalTrials.gov

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Lung Carcinoma
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bronchoscopy

Undergo bronchoscopy

DRUG

Extended Release Metformin Hydrochloride

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

80045

Rocky Mountain Regional VA Medical Center, Aurora

V5Z 1L3

BC Cancer Research Centre, Vancouver

V6T 2B5

University of British Columbia Hospital, Vancouver

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER